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Dupuytren Disease (DD) is a fibroproliferative disease of palmar fascias of the hand. The prevalence of DD 
has been the subject of several reviews, though an accurate description of the prevalence range in the 
general population, and of the relation between age and DD is lacking. 
Methods 
A systematic review was performed by searching Embase and Pubmed on database specific mesh terms, 
and in title and abstract for “Dupuytren”, “incidence”, and “prevalence”. Two reviewers independently 
assessed the papers using inclusion and exclusion criteria, and rated the included studies with a quality 
assessment instrument. In a meta-analysis the median prevalence, as function of age by gender, was 
estimated, accompanied with 95% prediction intervals. The observed heterogeneity in prevalence was 
investigated with respect to the quality of the study. 
Results 
Twenty-three of 199 unique identified papers were included. Number of participants ranged from 37 to 
97,537, aging 18-100 years. Prevalence varied from 0.6-31.6%. The quality of studies differed, but could not 
explain the heterogeneity between studies. The median prevalence was estimated at 12%, 21%, and 29% 
at ages 55, 65, and 75 respectively, based on the relationship between age and prevalence determined 
from ten studies.  
Conclusions 
We have been able to describe a prevalence range of DD in the general population. Furthermore, the 
relationship between age and prevalence of DD is given per gender, including 95% prediction intervals. 
Hereby, it is possible to determine the prevalence at a certain age for the total general population, and for 
men and women separately.  





Dupuytren Disease (DD) is a fibroproliferative disease which affects some of the palmar fascias of 
the hand. This results in the development of nodules and cords, which eventually may contract and give rise 
to flexion contractures of the affected fingers. 
The origin of DD has been attributed to both genetic and environmental factors. The results of 
several family studies, and more specific twin studies, suggested that DD has a strong genetic component.1-
3 In 2011, Dolmans et al. performed a genome wide association study in which nine genes that are 
associated with DD were identified.4 
Some environmental risk factors that have been associated with the presence of DD include 
excessive alcohol consumption, smoking, manual work and hand trauma.5,6 In addition, several diseases, 
such as diabetes mellitus and epilepsy, are thought to play a role in the etiology of DD.7-9 However, the role 
of these risk factors and diseases is not fully cleared, and the results of different studies are occasionally 
conflicting. 
Many articles about the prevalence of DD have been published.10-15 In these articles there is a wide 
range of prevalence rates, varying from 0.2% to 56% 16,17, as reported by Hindocha et al. in their literature 
review.18 This wide range, in our opinion, may at least partly be caused by the great heterogeneity between 
study populations, i.e. general population, participants with certain risk factors as well as patients with 
specific diseases. Suboptimal design of the included studies may also be a reason for the wide range. 
Until now, no systematic review was conducted to scrutinize the prevalence rates specifically in the 
general population. It is assumed that life expectancy will increase considerably in the coming decades19, 
and from our clinical experience we know that DD is a chronic disease of the elderly. Therefore, it will be 
important to enhance our knowledge about prevalence rates in the general population, and to be aware of 
changes in the prevalence across age. Furthermore, new treatment options have emerged, such as 
radiotherapy, percutaneous needle fasciotomy, and collagenase injection, and prevalence rates may be 
used to evaluate their cost effectiveness. 
The aim of this study is to come to a more accurate description of the range of the prevalence of DD 
in the general population. This will be done by reviewing the literature on prevalence of DD systematically, 
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combined with a quality assessment of the included studies. A secondary goal is to perform a meta-analysis 





A literature search was performed on 9th of May, 2012 in two bibliographical databases PubMed and 
Embase. PubMed was searched with the search strategy: ("Dupuytren Contracture"[Mesh] OR 
dupuytren*[TIAB]) AND ("Prevalence"[Mesh] OR prevalen*[TIAB] OR "Incidence"[Mesh] OR 
"incidence"[TIAB]). In Embase the following search strategy was imputed: dupuytren*:ab,ti AND 
('prevalence'/exp OR prevalen*:ab,ti OR 'incidence'/exp OR 'incidence':ab,ti) NOT [medline]/lim AND 
[embase]/lim. 
The search was updated on 24th of January, 2013 to include new publications, and the updated search was 
supplemented by automatically weekly derived updates from PubMed until 4th of August. No limits were 
implemented in our search queries.  
 
Assessment of relevant studies 
Two authors (RL and DB) independently assessed the studies in three rounds, based on predefined 
criteria (Textbox 1). If in the first round inclusion or exclusion criteria could not be assessed from the title 
and abstract, a full text analysis was performed. Of articles that were included after first evaluation, full text 
was assessed in two rounds, again by RL and DB separately. After each round, a meeting was held to 
discuss discrepancies and to reach consensus. The third author (PW) was consulted if no consensus could 
be reached. 
 
Quality assessment of included studies 
We used the scoring instrument of Cho20 to assess the quality of the studies, based on the review 
article of Shamliyan et al. on quality assessment tools for epidemiologic studies.21   
The instrument consists of 24 questions about study design, participants, methods to control bias, 
statistical analyses, reporting of results, and the conclusions drawn from the results.  
For each question respectively 2, 1, 0, and 0 points were awarded to the answers "Yes," "Partial," "No," and 
"Not applicable", in order to obtain an overall quality score for each article. 
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This was done for each question except for the question on study design; in that case 1 to 5 points were 
given (1 for case reports, 2 for time series or uncontrolled experiments, 3 for cohort or case-control studies, 
4 for nonrandomized control trials, and 5 for randomized control trials).20  
Total points awarded for the 24 questions were divided by the total possible points (the sum of the 
maximum points for each item, excluding "Not applicable" items) to generate a fraction between 0 and 1. A 
score of 1 represents the highest quality.20 
All articles that were included after the second full text round were scored with this instrument by RL 
and DB independently. The article by Lanting et al. was evaluated by DB and an independent clinical 
epidemiologist, to avoid a conflict of interest, since both did not participate in that publication. 
 
Data extraction and statistical analysis 
In a statistical analysis, we combined studies that provided information on prevalence and sample 
sizes for different age categories in a total population, or in males and females separately. The aim of this 
meta-analysis was to determine a population-averaged relationship between age and DD, and to study 
possible heterogeneity in this relationship between studies. The mid points of the age categories were used 
in a generalized linear mixed model. The form of the age-prevalence relationship was selected equal to an 
asymmetric logistic function with a random intercept for study to address possible heterogeneity. This model 
was applied to the data of males and females simultaneously with a random intercept for males and females 
that was correlated. A simpler model with only one random intercept was applied to the totals of males and 
females, since some studies did not provide data separately by gender. From the estimated models and the 
random effects, a range of age based predicted prevalences were estimated (i.e. 95% prediction intervals). 
Additionally, in case heterogeneity was present, it was investigated whether the overall quality score or the 
quality of study design affects the heterogeneity.  
In some of the studies, the prevalence was determined in patients with a specific disease, and in a 
control group. If that was the case, only the data from the control group were used. The calculation of the 






Results of literature search and assessment of relevant studies 
The literature search resulted in 212 articles. After excluding duplicates and critical appraisal of the 
studies by predefined criteria as mentioned in Textbox 1, 23 studies were included is this review (Figure 1). 
Two main reasons led to exclusion: firstly, the prevalence of DD was not determined, and secondly, 
the study population was not a general population. Consequently, all non-English papers were excluded by 
this selection. 
In Table 1 the details of all included studies are shown. Articles were published between 1972 and 
2013. In some studies, only data from the control group were used (noted as CG in Table 1). Several times 
these control groups were chosen from a population that sustained hand pathology.23-25 In two studies it was 
explicitly noted that participants in the control group did not suffer from hand pathology.26,27 
The total number of participants ranged from 37 to 97.537, in seven studies only males 
cooperated.28-34 Age ranged from 18 to 100 years, with an average above 50 years of age in 12 studies. In 
six studies age was only reported in age categories, without absolute number of participants in each 
category, so it was not possible to calculate a mean age (CAT in Table 1).25,26,33,35-37 
 The lowest prevalence found was 0.6% compared with 31.6% as highest prevalence over all age 
groups.12,38  In the studies of Descatha et al. and Lucas et al., DD was diagnosed in a different fashion 
compared with the rest of the studies. Descatha et al. did not diagnose palmar thickening as DD, and Lucas 
et al. excluded the thumb from examination.31,32 
The quality score is depicted in the last column of Table 1, this score ranged from 0.23 to 0.80.  
   
Results of quality assessment  
Table 2 shows in detail the results of the quality assessment per question, and Table 3 shows the 
score on the different questions per study. Question 2 is an open question which does not contribute to the 
final score. 
  The majority of studies reported the study question only partially. In 13% of the studies the inclusion 
and exclusion criteria were completely explained, while in 61% these criteria were not depicted at all. In 
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almost 80% of the papers, the subjects were not randomly selected from the target population, or this was 
not reported. Only one of the 23 studies reported a sample size justification.39 
Regarding the statistical analyses, in almost a quarter of the papers it was not reported which 
analyses were performed, and in only 52% the performed analyses were fully appropriate to answer the 
research question. The effect of confounders was most frequently corrected in the statistical analyses, and 
not beforehand in the study design.  
In 70% of the cases the conclusion of the study was fully supported by the findings, however, in one 
study the results point to a contrary conclusion than reported.25   
 
Explorative analysis 
The generalized linear mixed model indicated substantial heterogeneity between studies, meaning 
that the prevalence varies between studies. It was explored whether the overall quality score, and the sub 
score on the methods of a study (questions 1, 4, 7-9, 14-17, 19 in Table 3) were related to the 
heterogeneity. The goal of this analysis was to check whether selecting studies on quality would narrow the 
prevalence range substantially. The distance of each study to the median profile in Figure 2 was plotted 
against the variables of interest. No clear pattern was observed for the quality scores or the sub scores; 
both low quality studies and high quality studies appear on both sides of the median prevalence for all 
levels. This indicates that the quality of a study did not explain the variance in prevalence, so no studies 
were excluded for further analyses based on quality score. 
 
Relation between age and prevalence of DD 
A combined analysis of 10 studies12,15,24-26,35-37,39,42 representing information on prevalences for the 
population in different age groups showed an overall relationship that is visualized in the upper graph of 
Figure 2. In the middle and lower graph of Figure 2, this relationship is shown respectively for females (8 
studies12,15,26,35-37,39,42) and males (11 studies12,15,26,28,29,31,35-37,39,42). The prevalence is shown as well as the 
95% confidence intervals (inner dotted lines), taking into account the heterogeneity between studies. 
Furthermore, a 95% prediction interval is presented (outer dashed lines), which makes it possible to predict 
the prevalence at a certain age in the general population. For instance, the overall prevalence of DD is 
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estimated 12% at 55 years, and 29% at an age of 75 years. The prediction band can be used to estimate 
the a priori prevalence in a random sample at different ages. Clearly, the prevalence increases with rising 
age. Furthermore, the graphs show that the prevalence of DD in males is higher than in females. In addition, 
the age of onset is lower in males compared with the age of onset in females.   
Investigating the goodness-of-fit of the estimated models, the R2 was calculated between the 
observed numbers of DD, and the predicted numbers of DD from the model. For males the R2 was 
estimated at 99.5%, for females the R2 was equal to 93.0% and for males and females together the R2 was 
97.5%, which demonstrates a good fit of the generalized linear mixed model. This indicates that the models 
in Figure 2 are able to predict new observations with high certainty. This high goodness of fit may not seem 
in line with the observed outliers outside the prediction limits in Figure 2. However, several of these outliers 
were based on small number of subjects (Table 4). For instance, when only one subject is observed in an 
age category, the prevalence can only be estimated at either 100% of 0% depending on the outcome of DD. 





 Dupuytren Disease (DD) is an, often progressive, hand disorder, which can lead to contractures of 
the affected fingers. Prevalence rates differ widely in the literature, so we felt there was a need for a more 
thorough analysis. The primary goal of this systematic review was to come to a more accurate distribution of 
the prevalence of DD in the general population. A secondary goal was to perform a meta-analysis on the 
relation between age and prevalence of DD.  
To our knowledge, this systematic review is the first of its kind, since it focuses on prevalence rates 
specifically in the general population, and the quality of the studies was critically assessed. Other reviews 
have been written about prevalence rates of DD, but these reviews concern different kinds of populations, 
such as manual workers43, rock climbers44,45, and a mixture of healthy participants and patients with a 
specific disease.18 Furthermore, we performed a thorough meta-analysis to provide information on the 
relationship between age and DD. 
 After initial assessment using predefined inclusion and exclusion criteria, we could include 23 
studies investigating the general population, with a number of participants ranging from 37 to 97.537 in the 
age of 18 to 100 years. Prevalence in these studies varied from 0.6% to 31.6%, which is a smaller range 
than previously published.18 
 During the quality assessment of study design and reporting (see Table 2 and Table 3), we came 
across a number of noteworthy points. First of all, only few studies mentioned that they applied sampling to 
select their participants.15,23,31,35,39  However, three of these studies did not describe the method of 
sampling.23,31,35 If participants are not randomly selected, this increases the risk of selection bias, and 
makes it thereby difficult to extrapolate data from the studies. Secondly, only one study reported a sample 
size justification before the study.39 In an observational study, the accuracy of the estimates, i.e. the 
prevalence, is dependent on the sample size.46 If a sample size calculation is not accomplished on 
forehand, the results of the study might be less precise than intended. Finally, in only a quarter of the 
studies the statistical tests were fully stated, and in 52% of the studies the analyses were completely 
appropriate. To enlarge the reproducibility of the results, it is essential that such information is properly 
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documented. More importantly, to ensure that correct conclusions will be drawn, it is crucial that appropriate 
analyses are performed. 
In order to narrow the prevalence range, we intended to select studies for further analysis, based on 
their quality. The final overall quality score differed from 0.23 to 0.80. However, in the explorative analysis, 
no relation was found between this quality score, and the prevalence that was reported. This is in 
accordance with the findings in a meta-analysis by Descatha et al., in which the meta-odds ratio for manual 
work and vibration exposure of all studies was similar to the meta-odds ratio of only high quality studies.43  
Several articles have been published about the difficulties using an overall score to assess the 
quality of a study.47-49 One of the main issues in these articles is that with an overall quality score it is hard to 
discriminate between poor reporting and poor methodology of the study. Hence, it is advised to evaluate 
articles based on key components rather then an overall score.21,47,50 Therefore, we analyzed the relation 
between a high score on questions that relate to the methods of a study and the prevalence of DD. Still, no 
link was found, so we assumed that the current spread in prevalence was not based on a difference in 
quality of the studies, but on the heterogeneity of the study populations.   
We aimed to include studies with participants from the general population. In the majority of studies, 
participants were actually originating from the general population, such as inhabitants of a specific area. 
From 11 of the included studies, we used only the data from the control group. In three of these studies23-25, 
there might have been a chance that participants experienced hand pathology; it is unclear how this affects 
the prevalence.  
As mentioned in the results, in two studies DD was diagnosed differently than in the other 
studies.31,32 Although this did not change our prevalence range substantially, differences in diagnosing DD 
complicate the comparison of results. Preferably all stages of DD in all rays are taken into account, for 
example by using the classification of Iselin or Tubiana.51,52 Furthermore, there were differences in reporting 
age; six studies reported age in categories, without giving the actual range.25,26,33,35-37 The discrepancies in 
age reporting also impede comparison of prevalence rates of different studies. Fortunately, we have been 
able to use data of different age categories in our meta-analysis. 
It is well recognized that prevalence of DD increases with rising age, however, until now a thorough 
analysis on this relationship is lacking. In our meta-analysis, we investigated this relationship by using all 
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studies that provided information on prevalence of DD in different age categories. We have been able to 
present the relationship between age and DD, including 95% confidence intervals and 95% prediction 
intervals.The figures can be used to determine a common estimate and prediction interval for the 
prevalence of DD at different ages, both for the total population as well as for males and females separately. 
Nowadays, still little is known about the prevalence of DD in younger people of the general population, 
because one of the inclusion criteria in most studies was that participants appeared over fifty years of age. 
However, the relationship between age and prevalence presented in this paper already provides a first 
indication for prevalence at younger age.  
 
Conclusion 
 The prevalence of DD in the general population ranges from 0.6% to 31.6%. With the results of our 
meta-analysis, we have been able to present the relationship between prevalence of DD and age, including 
confidence intervals and prediction intervals. With the presented graphs it is possible to determine the 
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Textbox 1. Criteria for inclusion and exclusion  
Round 1. Title and abstract  
Inclusion criteria: 
- DD as research theme 
- General population as sample 
Exclusion criteria: 
- Case report 
- Case series 
- Review article 
- Subjects aged <18 years 
Round 2. First full text assessment 
Inclusion criteria: 
- Prevalence of DD as research theme 
Exclusion criteria: 
- Age is not reported 
- Physical examination to diagnose DD was 
not performed or not reported 
- Full text is not available 
Round 3. Second full text assessment 
Inclusion criteria: 
- Prevalence is calculated 
- Data is provided to calculate prevalence 
Exclusion criteria: 
- Unclear how DD is diagnosed 
- Outcome is ‘Dupuytren Contracture’, not 
further specified 
- Incidence was reported instead of prevalence 




Figure 1. Flow-chart of study selection procedure. 
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Table 1. Details of included studies. 
Authors Year Population N  Gender Age Prevalence (95%CI) Quality 
score 
     Mean  SD Range   
Arafa35  1984 Patients of fracture clinic (CG) 555 F and M CAT   16.0 [13.1 ; 19.4] 0.46 
Ardic23 2003 Non-diabetic patients of 
department of physical medicine 
and rehabilitation (division 
rheumatology) (CG) 
37 F and M 55.7 11.5 30-79 2.7 [1.0 ; 14.2] 0.44 
Attali40 1987 Patients of gastroenterology unit 
without alcoholism or chronic 
liver disease (CG) 
174 F and M 58.9 22.7  12.5 [8.1 ; 18.5] 0.49 
Aydeniz41 2008 Non-diabetic patients of public 
health clinic (CG) 
101 F and M 60.1 7.6  4.0 [1.1 ; 9.8] 0.51 
Bennett28 1982 Workers PVC manufacturing 
plant not involved with bagging 
or packing (CG) 
84 M 40.1   1.19 [0.0 ; 6.5] 0.46 
Burke29 2007 Miners seeking compensation 
for Hand-Arm Vibration 
Syndrome 
97537 M 53.5   8.13 [8.0 ; 8.30] 0.62 
Carson30 1993 Ex-military service pensioners in 
the Royal Hospital Chelsea 
400 M 75.9  65-99 13.8 [10.5 ; 17.5] 0.38 
Degreef12 2010 Visitors of markets in Flanders, 
Belgium 
500 F and M 70.4  50-100 31.6 [27.5 ; 35.9] 0.46 
Descatha31 2012 Employees in private sector in 
Pays de la Loire, France 
2161 M 38.5  20-59 1.25 [0.8 ; 1.8] 0.66 
Eadington13 1989 Normotensive, non-diabetic 
subjects, selected from 
inpatients, outpatients and 
hospital staff members (CG) 
150 F and M 51.2 17.4  18.0  [12.2 ; 25.1] 0.64 
Finsen36 2002 Residents of rural municipalities 
in Norway 
456 F and M CAT  50-80+ 7.5 [5.05 ; 9.87] 0.51 
Gudmundsson15 2000 Residents of Reykjavik and 
adjacent communes, Iceland 
2165 F and M 57.5  45-94 13.3 [11.9 ; 14. 8] 0.56 
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Lanting39 2013 Residents of Groningen, The 
Netherlands 




22.1 [19.3 ; 25.3] 0.80 
Lennox26 1993 Patients on geriatric ward, not 
admitted for hand pathology 
200 F and M CAT   30.0 [23.7 ; 36.9] 0.37 
Lucas32 2008 Civil servants of Pays de la 
Loire and Brittany, France 
2406 M 45.3 7.6  8.8 [7.7 ; 10.0] 0.64 
Mikkelsen42 1972 Residents of Haugesund, 
Norway 
15950 F and M 45.0  16-99 5.6 [5.3 ; 6.0] 0.46 
Noble25 1992 Patients of fracture clinic (CG) 100 F and M CAT .  8.0 [3.5 ; 15.2] 0.36 
Noble24 1984 Patients of fracture clinic (CG) 150 F and M 57.4   18.0 [12.2 ; 25.1] 0.28 
Pal27 1987 Non-diabetic subjects without 
musculoskeletal complaints 
(CG)  
75 F and M 44.0 
(median) 
 18-76 9.0 [3.8 ; 18.3] 0.49 
Rafter33 1980 Inpatients in acute medical and 
surgical wards 
403 M CAT .  17.1 [13.6 ; 21.2] 0.23 
Ravid38 1977 Non-diabetic patients of different 
departments of medicine (CG) 
1396 F and M 52.0  19-86 0.6 [0.3 ; 1.2] 0.49 
Thomas34 1992 Patients admitted to general 
surgical ward (CG) 
150 M 64.1  50-85 10.7 [6.2 ; 16.7] 0.46 
Zerajic37 2004 Visitors of public places in both 
urban and rural areas of Bosnia 
Herzegovina 
1207 F and M CAT .  25.4 [23.0 ; 28.0] 0.59 
CG: control group, N: number of participants, SD: standard deviation, CI: confidence interval, IQR: inter quartile range, 






Table 2. Quality assessment of included studies per question. 
   Answer: Yes Partial No NA 
 Question n % n % n % n % 
1 Study design †         
2 What was the study question? ‡         
3 Was the study question sufficiently described? 5 22% 15 65% 3 13% 0 0% 
4 Was the study design appropriate to answer the study 
question? 
21 91% 2 9% 0 0% 0 0% 
5 Were both inclusion and exclusion criteria specified? 3 13% 6 26% 14 61% 0 0% 
6 For case studies only: Were patient characteristics adequately 
reported?* 
0 0% 0 0% 0 0% 23 100% 
7 Were subjects appropriate to the study question? 19 83% 4 17% 0 0% 0 0% 
8 Were control subjects appropriate? 12 52% 6 26% 5 22% 0 0% 
9 Were subjects randomly selected from the target population? 5 22% 0 0% 18 78% 0 0% 
10 If subjects were randomly selected, was the method of random 
selection sufficiently well described? 
1 4% 1 4% 3 13% 18 78% 
11 If subjects were randomly allocated to treatment groups, was 
method of random allocation sufficiently described?** 
0 0% 0 0% 0 0% 23 100% 
12 If blinding of investigators was possible, was it reported?** 0 0% 0 0% 0 0% 23 100% 
13 If blinding of subjects to intervention was possible, was it 
reported?** 
0 0% 0 0% 0 0% 23 100% 
14 Was measurement bias accounted for by other methods than 
blinding? 
6 26% 11 48% 6 26% 0 0% 
15 Were known confounders accounted for by study design? 5 22% 3 13% 13 57% 2 9% 
16 Were known confounders accounted for by analysis? 9 39% 5 22% 7 30% 2 9% 
17 Was there a sample size justification before the study? 1 4% 0 0% 22 96% 0 0% 
18 Were post hoc power calculations or confidence intervals 
reported for statistical non significant results? 
4 17% 4 17% 15 65% 0 0% 
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19 Were statistical analyses appropriate? 12 52% 5 22% 6 26% 0 0% 
20 Were the statistical tests stated? 6 26% 12 52% 5 22% 0 0% 
21 Were exact values or confidence intervals reported for each 
test? 
5 22% 13 57% 5 22% 0 0% 
22 Were attrition of subjects and reason for attrition recorded? 4 17% 3 13% 16 70% 0 0% 
23 For those subjects who completed the study; were results 
completely reported? 
15 65% 7 30% 1 4% 0 0% 
24 Do the findings support the conclusions? 16 70% 6 26% 1 4% 0 0% 
n: number of studies, %: percentage, NA: not applicable, † See Table 3, ‡ Open question which does not contribute to 
final score, * Case studies were not included, so question 6 was not applicable for each of the included articles, ** 






Table 3. Quality assessment of included studies per study.  
 
† Questions: 1: Study design, 2: Research question, 3: Study question sufficiently described, 4: Study design appropriate to answer study question, 5: Inclusion 
and exclusion criteria specified, 6: Case studies: patient characteristics adequately reported, 7: Subjects appropriate to study question, 8: Control subjects 
appropriate, 9: Random selection of subjects, 10: Method of random selection sufficiently well described, 11: Random allocation to treatment group sufficiently 
described, 12: Blinding of investigators to intervention reported, 13: Blinding of subjects to intervention reported, 14: Measurement bias accounted for by methods 
other than blinding, 15: Known confounders accounted for by study design, 16: Known confounders accounted for by analysis, 17: Sample size justification, 18: 
Post hoc power calculations or confidence intervals reported for statistically non significant results, 19: Appropriate statistical analyses, 20: Statement of statistical 
tests, 21: Exact values of confidence intervals reported for each test, 22: Reporting of attrition of subject and reason for attrition, 23: Results completely reported 
for subjects who completed the study, 24: Findings support the conclusion.  
Question 1 was scored 3 (cohort design) or 2 (cross-sectional design), other questions were scored 2 (yes), 1 (partial), 0 (no), NA (not applicable).  
The score was calculated by dividing the total points by the maximum possible points. A higher score represents a higher quality.  
Author 
Questions†    
1 2‡ 3 4 5 6* 7 8 9 10 11** 12** 13** 14 15 16 17 18 19 20 21 22 23 24 Total Max. points  Score 
Arafa35  2  0 1 0 NA 2 1 2 0 NA NA NA 2 2 1 0 0 0 1 1 0 2 2 19 41 0.46 
Ardic23  2  1 2 0 NA 2 0 2 0 NA NA NA 1 0 2 0 0 1 1 0 0 2 2 18 41 0.44 
Attali40  2  1 2 0 NA 2 2 0 NA NA NA NA 0 0 2 0 0 2 1 1 0 2 2 19 39 0.49 
Aydeniz41 2  1 2 1 NA 2 2 0 NA NA NA NA 2 2 0 0 0 1 1 1 0 2 1 20 39 0.51 
Bennett28 2  1 2 0 NA 2 2 0 NA NA NA NA 1 0 2 0 0 1 1 0 0 2 2 18 39 0.46 
Burke29  2  2 2 0 NA 2 2 0 NA NA NA NA 1 0 2 0 2 2 2 2 0 1 2 24 39 0.62 
Carson30  2  0 2 0 NA 2 2 0 NA NA NA NA 1 0 1 0 0 0 0 1 0 2 2 15 39 0.38 
Degreef12  2  1 2 2 NA 2 2 0 NA NA NA NA 2 0 0 0 0 0 0 1 0 2 2 18 39 0.46 
Descatha31  2  1 2 2 NA 2 2 2 0 NA NA NA 1 0 2 0 2 2 1 1 1 2 2 27 41 0.66 
Eadington13  2  2 2 2 NA 2 1 0 NA NA NA NA 1 1 2 0 1 2 2 1 1 2 1 25 39 0.64 
Finsen36  2  1 2 1 NA 2 0 0 NA NA NA NA 0 0 1 0 1 2 2 2 2 1 1 20 39 0.51 
Gudmundsson15 3  1 2 0 NA 2 2 2 1 NA NA NA 1 0 2 0 1 2 1 1 0 1 1 23 41 0.56 
Lanting39 2  2 2 0 NA 2 2 2 2 NA NA NA 1 2 2 2 2 2 2 2 0 2 2 33 41 0.80 
Lennox 26 2  1 2 0 NA 1 0 0 NA NA NA NA 1 NA NA 0 0 1 1 1 0 1 2 13 37 0.37 
Lucas32 2  1 2 1 NA 1 2 0 NA NA NA NA 1 0 2 0 2 2 2 2 1 2 2 25 39 0.64 
Mikkelsen42 2  1 2 1 NA 2 0 0 NA NA NA NA 2 NA NA 0 0 0 0 0 2 2 2 16 35 0.46 
Noble 24 2  0 2 0 NA 2 1 0 NA NA NA NA 0 2 0 0 0 0 0 1 0 0 1 11 39 0.28 
Noble25 2  1 2 0 NA 1 1 0 NA NA NA NA 0 1 0 0 0 2 1 1 0 2 0 14 39 0.36 
Pal27 2  2 2 1 NA 2 2 0 NA NA NA NA 2 0 0 0 0 1 1 1 2 1 0 19 39 0.49 
Rafter33 2  1 1 0 NA 1 2 0 NA NA NA NA 0 0 0 0 0 0 0 0 0 1 1 9 39 0.23 
Ravid38 2  2 2 0 NA 2 1 0 NA NA NA NA 0 2 1 0 0 2 1 0 0 2 2 19 39 0.49 
Thomas34  2  1 2 0 NA 2 1 0 NA NA NA NA 1 0 1 0 0 2 1 2 0 1 2 18 39 0.46 
Zerajic37 2  1 2 1 NA 2 0 0 NA NA NA NA 2 1 0 0 1 2 2 1 2 2 2 23 39 0.59 
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‡ Open question which does not contribute to the final score. 
* Case studies were not included, so question 6 was not applicable for each of the included articles.  





Figure 2. Relationship between age and DD.  Upper graph: totals, middle graph: females, lower graph: 
males. Bold line: estimated prevalence, dotted line: 95% confidence interval, dashed line: 95% prediction 
interval, dots: individual prevalence estimates used in the analysis. 
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Table 4. Studies outside prediction intervals 
Population Age cat. Author n DD n total % DD 95% PI 
Total <30 Arafa 1 34 2.94 0.02 – 0.61 
 30-34  Mikkelsen 1 1043 0.10 0.12 – 2.89 
 30-39 Arafa 4 47 8.51 0.18 – 4.38 
 30-39 Noble (1984) 1 5 20 0.18 – 4.38 
 50-59 Finsen 2 103 1.94 2.53 – 27.46 
 61-65 Degreef 32 86 37.21 5.25 – 37.20 
 75-79 Zerajic 43 72 59.72 12.26 – 49.43 
 76-80 Lanting 30 57 52.63 12.84 – 50.15 
 >80 Finsen 0 24 0 16.76 –  54.41 
 95-99 Mikkelsen 0 3 0 24.32 – 60.98 
Males <30 Descatha 0 491 0 0.06 – 4.22 
 55-64 Bennet 0 9 0 2.84 – 42.03 
 75-79 Zerajic 30 40 75 7.60 – 53.80 
  76-80 Lanting 18 24 75 7.95 – 54.34  
 >80 Finsen 0 7 0 10.38 – 57.52 
 80+ Zerajic 24 40 60 9.41 – 56.35 
 81-85 Lanting 8 14 57.14 9.80 – 56.83 
 >90 Lennox 4 6 66.67 14.52 – 61.62 
 90-94 Mikkelsen 1 1 100† 13.45 – 60.68 
 95-99 Burke 0 1 0 15.60 – 62.53 
 95-99 Mikkelsen 0 1 0 15.60 – 62.53 
Females 81-85 Lanting 8 17 47.06 0.25 – 46.83 
Age cat: age category, n DD: participants with DD, n total: total participants, % DD: percentage of participants with DD, 
95% PI: 95% prediction interval 
† Outlier not visible in Figure 2 (Y-axis ranges from 0-80%) 
 
 
